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B I O C H E M I S T R Y
Crystal structure of rhodopsin in complex with a mini-Go 
sheds light on the principles of G protein selectivity
Ching-Ju Tsai1*, Filip Pamula1,2, Rony Nehmé3†, Jonas Mühle1, Tobias Weinert1, Tilman Flock1,2,4, 
Przemyslaw Nogly1,2, Patricia C. Edwards3, Byron Carpenter3‡, Thomas Gruhl1,2, Pikyee Ma1, 
Xavier Deupi1,5, Jörg Standfuss1, Christopher G. Tate3, Gebhard F. X. Schertler1,2*
Selective coupling of G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptors (GPCRs) 
to specific G-protein subtypes is critical to transform extracellular signals, carried by natural ligands and clinical 
drugs, into cellular responses. At the center of this transduction event lies the formation of a signaling complex 
between the receptor and G protein. We report the crystal structure of light-sensitive GPCR rhodopsin bound to 
an engineered mini-Go protein. The conformation of the receptor is identical to all previous structures of active 
rhodopsin, including the complex with arrestin. Thus, rhodopsin seems to adopt predominantly one thermody-
namically stable active conformation, effectively acting like a “structural switch,” allowing for maximum efficiency 
in the visual system. Furthermore, our analysis of the well-defined GPCR–G protein interface suggests that the 
precise position of the carboxyl-terminal “hook-like” element of the G protein (its four last residues) relative to the 
TM7/helix 8 (H8) joint of the receptor is a significant determinant in selective G protein activation.
INTRODUCTION
G protein (heterotrimeric guanine nucleotide–binding protein)–coupled 
receptors (GPCRs) are a large family of membrane receptors that in-
teract with heterotrimeric G proteins to transform extracellular 
signals into cellular responses. Selective coupling of GPCRs to specific 
G-protein subtypes is a critical step that determines their physiology 
and their response to natural ligands and clinical drugs. While pre-
vious studies have revealed regions on GPCRs and G proteins involved 
in selectivity (1, 2), the molecular details remained elusive. These 
details can be elucidated by examining and comparing the structure 
of GPCR–G protein complexes, which lie at the center of this signal 
transduction event.
Crystal structures of GPCR signaling complexes have been deter-
mined only for the Gs protein and arrestin. Several techniques are 
being used to stabilize these GPCR–G protein complexes for structural 
determination, such as fusion of T4 lysozyme on the receptor and the 
use of a nanobody (3) or mini-G protein (4), or the creation of a fu-
sion chimera in the rhodopsin-arrestin complex (5). Mini-G proteins 
comprise the guanosine triphosphatase (GTPase) domain of the  
subunit of heterotrimeric G proteins and are fully capable of stabi-
lizing GPCRs in their active state, generating characteristic changes in 
agonist affinity and recapitulating G protein specificity in vivo (6–8).
The light-sensitive visual receptor rhodopsin is the prototypical 
class A (rhodopsin-like) GPCR. It is activated by light-induced isomer-
ization of the covalently bound ligand retinal. Upon activation, rho-
dopsin couples to and activates Gt (transducin), a member of the 
Gi/o subfamily (2), thus triggering the cyclic guanosine monophosphate 
cascade. At the center of this signal transduction mechanism lies the 
formation of a complex between active rhodopsin and the G protein. 
Rhodopsin is the first GPCR that had structures determined in the 
inactive and active states with and without agonist (9) and in an 
arrestin-bound state (5). In addition, rhodopsin is the only GPCR 
for which structures of human disease mutants have been solved 
(10, 11). Comparisons of these structures revealed that rhodopsin 
activation results in the opening of a cleft on the cytoplasmic side of 
the receptor and the formation of a binding cavity for the C-terminal 
domain (5) of Gt. The rhodopsin system has significantly contributed 
to our understanding of class A GPCR activation (12–16).
The organization of rhodopsin and the G proteins Gi and Gt in 
the signaling complex has been recently analyzed by combining site- 
directed spin labeling and electron paramagnetic resonance spectros-
copy data with molecular dynamics simulations (17, 18). In addition, 
a mutagenesis analysis performed with native rhodopsin and Gi al-
lowed for the location of residues involved in the stabilization of the 
complex (19). While these results have provided valuable information 
on the overall arrangement of the complex, a high-resolution, three- 
dimensional (3D) map of the interaction interface is still missing. Ob-
taining additional structures with this G protein subtype will allow 
us to identify the structural elements defining G protein selectivity.
RESULTS
Here, we report the crystal structure of the stabilized constitutively 
active mutant of bovine rhodopsin N2C/M257Y/D282C in complex 
with mini-Go. These three mutations do not affect negatively the 
structure or functional properties of active rhodopsin (20). Attempts 
at creating a mini-G protein from Gt were unsuccessful, and there-
fore, we used the related Go (62% sequence identity) (6). Similar to 
the full heterotrimeric G protein (21), mini-Go couples effectively to 
light-activated rhodopsin solubilized in detergent, creating a stable 
complex that shows the characteristic spectral properties of the fully 
active state of rhodopsin bound to all-trans retinal (fig. S1A). The 
complex was purified in octyl glucose neopentyl glycol (OGNG) and 
crystallized by vapor diffusion at 4°C. Merging diffraction data from 
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five crystals allowed structure determination by molecular replacement 
and refinement up to a resolution of 3.1 Å (Material and Methods, 
table S1, and fig. S2). Crystals grew with p61 symmetry, in which the 
crystal packing is mainly mediated by hydrophilic contacts between 
mini-Go molecules. The orthosteric ligand-binding pocket contains 
only partial density for the agonist all-trans retinal (fig. S3), but the 
electron density is well defined at the mini-Go binding interface in 
the cytoplasmic cleft (Fig. 1).
Mini-Go binding interface to rhodopsin
The crystal structure of the engineered G protein mini-Go bound to 
rhodopsin displays a high overall similarity to mini-Gs bound to the 
adenosine A2A receptor [A2AR; root mean square deviation (RMSD), 
1.11 Å] (4), as well as to the guanosine triphosphate (GTP)–binding 
domains of heterotrimeric Gs bound to the 2-adrenergic receptor 
(2AR; RMSD, 1.17 Å) (fig. S4A) (3). The protein-protein interfaces 
of mini-Go and rhodopsin in the complex are composed of 17 resi-
dues and 23 amino acid residues (Fig. 2), with a surface area of 1104 
and 1375 Å2, respectively. An evolutionary analysis (22) classifies this 
interface as biological (that is, not as merely a crystallographic con-
tact). The regions on mini-Go that make contact with the receptor 
comprise the 4-6 loop, the 6 sheet, and the 5 helix (Figs. 1 and 2 
and fig. S5). In the receptor, the major contact regions to mini-Go 
are located across the cytoplasmic ends of transmembrane helices 
TM2, TM3, TM5, TM6, and the TM7/H8 joint, with additional con-
tacts mediated by the ICL3. These contact interfaces agree with a 
previous cross-linking study using rhodopsin mutants and native 
transducin (23) and with a mutagenesis analysis performed with 
native rhodopsin and Gi mutants (19). These data, combined with 
the structural similarities to existing GPCR–G protein complexes, 
strongly suggest that the complex between rhodopsin and mini-Go 
recapitulates the main features (orientation and contact interface) of 
the native interaction with Gt.
The C-terminal portion of the 5 helix in mini-Go contributes most 
of the interactions to the receptor, as previously observed in Gs coupled 
to other GPCRs (Figs. 2C, 3, and 4A). In contrast, the contacts that we 
observe between the 6 sheet and the receptor are not present between 
either A2AR (4) or 2AR (3) and Gs; this is probably a consequence of the 
different modes of binding of Go to rhodopsin (see below) (18). In addi-
tion, the contacts between the helical ICL2 of A2AR, 2AR, and the sero-
tonin 5-HT1B receptor (5-HT1BR) (24) and the 2-3 loop/3 sheet in 
the  subunit of Gs are absent in the rhodopsin/mini-Go structure, in 
which ICL2 is unstructured (Fig. 3A). Thus, these differences may re-
flect a certain degree of plasticity in the interface between GPCRs and G 
proteins outside the 5 helix–binding crevice.
The residues in rhodopsin involved in making contacts with 
mini-Go are also very similar to those between A2AR or 2AR and 
Gs, although there are some subtle differences (Fig. 4A). Only in 
rhodopsin and class B GPCRs are there contacts mediated by TM2. 
Moreover, the contacts with TM7/H8 are more prominent in Go- than 
in Gs-coupled complexes. There are also differences in the number 
of residues in each structural element making contact to the  sub-
unit. In particular, the smaller outward movement of TM6 in the 
rhodopsin/mini-Go structure, coupled with the different tilt of the 
5 helix in the G protein, results in most of the rhodopsin/mini-Go 
contacts being in TM6 and fewer in TM5 (Figs. 1C, 3, and 4A). In 
contrast, in the 2AR/Gs structure and the A2AR/mini-Gs structure, 
most of the contacts are observed in TM5 and the end of TM3 run-
ning into ICL2 (Figs. 3 and 4A).
In summary, the contact residues in the complex interfaces 
spread over the cytoplasmic region of the receptors, and we cannot 
observe concrete interaction patterns. Thus, the selectivity between 
receptors and G proteins is not just encoded in the 2D protein se-
quence of the effector-binding site but rather in its 3D shape.
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Fig. 1. Structure of the rhodopsin/mini-Go complex. Rhodopsin is colored in 
a rainbow spectrum with the N terminus in blue and the C terminus in red. 
Mini-Go is shown in gray. Side chains are shown as sticks with carbon atoms in 
the same color as the backbone, oxygen in red, nitrogen in blue, sulfur in yel-
low, and the agonist all-trans retinal in light brown. Electron densities of the 
2Fobs-Fcalc map are contoured in a gray mesh at a 1.5 cutoff. (A) Overall view 
of the rhodopsin/mini-Go complex. Specific regions are detailed in the adja-
cent panels. (B) The ionic interaction between E1343.49 and R1353.50 at the 
D/ERY motif is broken; opening of this interhelical ionic lock is one of the 
hallmarks of GPCR activation. The constitutively activating M2576.40Y mutation 
assists in stabilizing the extended active conformation of R1353.50, as observed 
in the structure of this mutant bound to a Gt-derived peptide (20). (C) Contact 
interface between the C terminus of mini-Go and TM2 and TM6 in the receptor. 
(D) Contact interface between the C terminus of mini-Go and TM3 and TM7 in 
the receptor. The last four residues of the G protein (C-terminal hook) are 
located between R1353.50 and the joint between TM7 and helix 8 (H8). (E) Con-
tact interface between the 6 sheet in mini-Go and intracellular loop 3 (ICL3) in 
the receptor.
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Selectivity between receptor and G protein
The major difference between the Go- and Gs-GPCR complexes lies 
in the pose of the C-terminal 5 domain within the effector-binding 
site, with a difference in tilt angle of about 30° (Fig. 3 and fig. S4B). 
Remarkably, the last four amino acid residues of the 5 helix in Gi/o 
and Gs fold in an identical “hook-like” structure upon binding the 
receptor (3, 4, 20). However, their different side chains mold these 
elements into dissimilar shapes (Fig. 4B). This short C-terminal hook 
and the adjacent residues in 5 all make contacts to the receptor 
and are the most important structural elements in defining the sub-
type specificity of G proteins (2, 25–27).
The degree of opening in the cytoplasmic binding cavity partially 
determines the overall placement of the C-terminal hook, as its last 
two residues interact with the “displaced” cytoplasmic domains of 
TM5/6 (Figs. 3C and 4C). This hook also latches to TM3 [a struc-
tural hub of the GPCR fold located in the opposite side of the bind-
ing cavity (28)] by a subtype-specific interaction [Gi/o, Cys351H5.23; 
Gs, Tyr391H5.23; the residue numbering refers to the human wild-
type Go1 subunit (UniProtKB P09471), and the superscripts refer 
to the common G numbering system (25)] with Arg3.50 [conserved 
in class A GPCRs; superscripts in receptor residue numbers refer to 
the Ballesteros-Weinstein general numbering scheme (29)]. As a 
result, the hook locates at the interface between TM5/6 and the 
TM7/H8 joint in the binding cavity of the receptor. We observed 
that the conserved Gly352H5.24 of mini-Go forms a backbone–side 
chain interaction with Asn3108.47 in the receptor, placing it very 
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Fig. 2. Contact interface between rhodopsin and mini-Go. (A) Secondary structure of bovine rhodopsin. Residues that are within 3.9 Å of mini-Go are highlighted in colors 
matching those in Figs.  1A, 2C, and  4A. The gray regions are not determined in our structure. (B) Secondary structure of mini-Go. Residues that are within 3.9 Å of rhodopsin are 
highlighted in colors matching those in Figs.  2C and 4A. The dashed line represents the region that is not determined in the structure. (C) Table displaying the residue- residue 
contacts and distances between rhodopsin and mini-Go; the right two columns show for each residue in mini-Go if the corresponding position in Gt1 (UniProtKB P04695) 
and Gs (UniProtKB P04896) holds the same residue or not. Residue-residue interactions are colored blue (3.2 to 3.9 Å) and gray (shorter than 3.2 Å), while polar interac-
tions are labeled in salmon pink. The rhodopsin and mini-Go models used to calculate the distances contained virtual hydrogen atoms added during structure refinement.
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close to the TM7/H8 joint (Fig. 3C). In contrast, Gs has a much 
bulkier Glu392H5.24, which rests between the TM7/H8 turn and the 
TM5/6, interacting with Lys2706.32 (Figs. 3C and 4C). As a result, 
the relative orientation between the C-terminal hook and TM7/H8 
of the receptor is the main factor that differentiates the binding 
of Gi/o and Gs. Thus, GPCRs could modulate their selectivity for G 
proteins by shaping the cytoplasmic binding cavity to fit the C- 
terminal hook in a specific pose that results in a pulling motion of 
the 5 helix in the G protein, leading to its activation (30, 31). In Gi, 
this pose requires that the C-terminal hook packs its backbone tightly 
to the TM7/H8 turn. In contrast, recognition of the Gs C-terminal 
hook involves a structurally looser interaction with the TM7/H8 joint 
and TM5/6.
Two conformationally distinct states of rhodopsin
The reaction pathway of rhodopsin activation has been delineated in 
great detail using a variety of spectroscopy methods, revealing the exis-
tence of several identifiable intermediate states (15, 16). Furthermore, 
the structure of some of these intermediates has been determined 
by x-ray and electron crystallography (9). The early agonist-bound 
intermediates batho, lumi, and meta I form in microseconds and 
show only minor structural changes limited to the ligand-binding 
pocket. Similar small and local changes have also been observed in 
other agonist-bound inactive-state GPCR structures (32, 33). In con-
trast, transition to later stages in rhodopsin activation (meta IIa, 
meta IIb, and meta IIbH+) involves the opening of a cytoplasmic 
effector-binding site within a few milliseconds through the relocation 
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Fig. 3. Comparison of the G protein binding interface in GPCR–G protein complexes. Structures of rhodopsin/mini-Go, 5HT1BR/mini-Go (PDB ID: 6G79), A2AR/mini-Gs 
(PDB ID: 5G53), and 2AR/Gs (PDB ID: 3SN6) superimposed to the C atoms of rhodopsin. Receptors are colored in rainbow spectrum. (A) Side view of the complex struc-
tures. The orange and pink areas serve as a reference for the locations of TM6 in rhodopsin and the C-terminal 5 helix of mini-Go bound to rhodopsin, respectively. 
(B) Cytoplasmic view of the binding interface between receptors and G proteins. The receptors are shown as surfaces, and the C-terminal 5 helices of G proteins are 
shown as gray helices. The numbers mark the positions of the cytoplasmic end of TM1 to TM7 and H8. (C) Detailed view of the contact interface between the TM7/H8 joint 
(N3108.47 in rhodopsin, S3727.56 in 5HT1BR, R2917.56 in A2AR, and R3287.55 in 2AR) and the C-terminal hook (CGLY in Go and YELL in Gs).
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of the cytoplasmic end of TM6. The equilibrium between these late 
active states is partially regulated by subtle changes, such as in the 
protonation state at the cytoplasmic D/ERY motif (ionic lock) (13) 
or in the electronic properties of retinal (34). All identified spectro-
scopic states of rhodopsin fall into two main structural categories: 
inactive (including the inverse agonist-bound state and the agonist- 
bound early active intermediates) and active (apoprotein at low pH, 
agonist-bound late active states and arrestin-bound rhodopsin). 
The active conformation of rhodopsin displays a relatively small open-
ing in the cytoplasmic effector-binding site. To date, it has been un-
clear whether this was a true feature of rhodopsin bound to Gt and, 
by extension, of other GPCRs bound to Gi/o.
Surprisingly, the structure of rhodopsin in complex with mini-
Go is virtually identical to all the previous structures of active rho-
dopsin (average RMSD, 0.51 ± 0.07 Å; Figs. 5 and 6A and table S2) 
(5, 20, 35–38). Thus, our results show that a GPCR can expose an 
identical site for the recognition of the 5 helix of G and the finger 
loop of arrestin (Fig. 5). Rhodopsin thus effectively acts like a struc-
tural switch upon activation, adopting predominantly two thermo-
dynamically stable conformational states, an inactive state and an 
active state. In contrast, spectroscopic and structural studies suggest 
that GPCRs that bind diffusible ligands exist as an ensemble of 
conformations that include a number of inactive, intermediate, and 
active conformations (1, 39). Accordingly, their structures show a 
higher degree of variability (Fig. 6A).
DISCUSSION
The crystal structure of rhodopsin bound to an engineered mini-Go 
protein provides new insights into the molecular basis of GPCR–G 
protein recognition and selectivity. Comparison with existing com-
plexes suggests that the sequence of the binding interface alone 
does not determine selectivity (Fig. 4A). On the other hand, we no-
tice that the interactions between ICL2 and ICL3 of the GPCRs and 
the GTPase domain of G proteins show a certain degree of plas-
ticity, which could account for selective protein-protein interac-
tions. In addition, the different extent in the movement of TM6 
of GPCRs upon activation has been proposed to play a fundamental 
role in G protein selectivity (30, 31). While all these factors probably 
contribute to pulling the 5 helix to selectively activate specific 
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G proteins, we suggest that another significant determinant in this 
mechanism is the precise placement of the C-terminal hook-like 
element of the G protein (its last four residues) relative to the TM7/
H8 joint.
Activation of GPCRs involves a precise coupling between the 
physicochemical properties of their ligands and the dynamic properties 
of the receptor that results in the engagement and activation of intra-
cellular signaling proteins to promote downstream signaling. GPCRs 
that bind diffusible ligands have been shown to exist in an ensemble of 
conformations (Fig. 6B) (40). We show here that the visual receptor 
rhodopsin, on the other hand, functions like a “conformational switch” 
upon activation. This behavior remains even when the covalently 
bound ligand retinal is replaced by diffusible, pharmacologically de-
signed compounds (fig. S6) (41), suggesting that this is an inherent 
property of the receptor. This remarkable property of rhodopsin is 
likely related to the control of visual perception. First, a stable inactive 
conformation (in combination with other adaptations such as the pres-
ence of high local concentrations of both rhodopsin and G proteins in 
the rod photoreceptor membranes) allows for a tight control of basal 
activity, which is critical to reduce dark noise in visual systems. In 
addition, by having a unique active conformation, binding to G 
proteins and the turnover time for allowing arrestin binding after 
receptor phosphorylation are probably optimized, allowing for the 
activation of about 600 Gt molecules per second (42).
The structure of rhodopsin bound to mini-Go presented here adds 
a key piece to the gallery of states along its activation pathway, making 
rhodopsin the best-described GPCR in terms of structure. We can 
now sequentially track the conformations of a GPCR from its in-
active state to agonist-induced activation, G protein coupling, and bind-
ing to arrestin. Furthermore, the structure provides new insights into 
the binding interface between activated GPCRs and Gi/o proteins. 
This information advances our understanding of GPCR–G protein 
TM7
TM6
TM5
Rho/mini-Go Rho/arrestin
Arrestin 
finger loop 
Mini-Go 5
H8
TM7/H8 joint
C-terminal 
hook
Fig. 5. Structural comparison between rhodopsin complexes. (Top) Comparison of the rhodopsin/mini-Go complex (left) and the arrestin- bound structure (PDB ID: 5W0P; 
right) shows that rhodopsin exposes an identical site for the recognition of the 5 helix of G and the finger loop of arrestin. (Bottom) Detail of the G protein and arrestin 
binding interfaces viewed parallel to the cell membrane.
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selectivity and how GPCR conformations promote certain signaling 
pathways.
MATERIALS AND METHODS
Protein preparation
Mini-Go was prepared as described (6, 43). The N2C/M257Y/D282C 
mutant of bovine rhodopsin was expressed in human embryonic 
kidney (HEK) 293 GnTI− cells as described (20, 44). Buffers for 
every purification step were cooled to 4°C before use, and the steps 
after the addition of 9-cis retinal were performed under dim red light 
before light activation of rhodopsin. HEK293 cells were homogenized 
in phosphate-buffered saline (PBS) buffer and then solubilized by 
supplementing dodecyl maltoside (DDM) (Sol-Grade, Anatrace) to 
1.25% (w/v). After gentle mixing for 1 hour, the cell lysate was 
centrifuged at 200,000g for 1 hour to remove unsolubilized residual. 
The rhodopsin apoprotein in the solubilisate was captured using 
immunoaffinity agarose resin coupled to 1D4 antibody. The resin 
was collected and washed with 10 column volume (CV) of PBS 
buffer containing 0.04% DDM, and then 2 CV of PBS buffer con-
taining 0.04% DDM and 50 mM 9-cis retinal (Sigma-Aldrich) or 
11-cis retinal (National Institutes of Health and Hoffmann–La Roche) 
was mixed with the resin overnight in the dark. The resin was collected 
and washed sequentially with 15 CV of PBS buffer containing 0.04% 
DDM; 10 CV of buffer containing 20 mM Hepes (pH 7.5), 100 mM 
NaCl, and 0.12% (w/v) OGNG (Anatrace); and 5 CV of buffer con-
taining 20 mM Hepes (pH 7.5), 50 mM NaCl, 1 mM MgCl2, and 0.12% 
OGNG. Dark-state rhodopsin was eluted thrice with 1.5 CV of buffer 
containing 20 mM Hepes (pH 7.5), 50 mM NaCl, 1 mM MgCl2, 0.12% 
OGNG, and 80 M 1D4 peptide TETSQVAPA for more than 2 hours 
each time. Eluted protein was concentrated using an Amicon Ultra 
concentrator [molecular weight cutoff (MWCO), 50,000] to 5 to 
10 mg/ml. The concentrated protein was subjected to deglycosylation 
using the endoglycosidase F1 (Endo F1) at 1:100 (w/w) ratio over-
night at 4°C. The deglycosydated rhodopsin was mixed with mini-Go 
at the molar ratio of 1:1.2 in the presence of apyrase (25 mU/ml; 
New England BioLabs), incubated for 30 min, and then irradiated with 
light passed through a 495-nm long-pass filter, followed by another 
30-min incubation in the dark. The rhodopsin/mini-Go mixture was 
concentrated using an Amicon Ultra concentrator (MWCO, 50,000) 
and subjected to size exclusion chromatography on a Superdex 200 
Increase 10/300 GL column (GE Healthcare) using a buffer contain-
ing 20 mM Hepes, 0.4 mM MgCl2, and 0.12% OGNG. The eluted 
fractions were examined by SDS–polyacrylamide gel electrophoresis 
(PAGE) (fig. S1D), and those fractions containing pure rhodopsin/
mini-Go complex were pooled and concentrated to 8 mg/ml for crystal-
lization. The ultaviolet-visible spectrum of the final sample was mea-
sured to optically evaluate the isoform of retinal in rhodopsin, showing 
an OD280/OD380 (ratio of optical density between 280 and 380 nm) of 
1.8 in rhodopsin/mini-Go in contrast to 1.6 in light-activated rhodopsin.
The detergent OGNG was selected from a screening experiment, 
where rhodopsin was stable in both the dark and light states and upon 
mini-Go binding. Deglycosylation was a critical step for obtaining 
crystals of the rhodopsin/mini-Go complex. Peptide N-glycosidase 
A
6FUF + agonist all-trans retinal 
5W0P + agonist all-trans retinal
4A4M + agonist all-trans retinal
3CAP + (-)
3PXO + agonist all-trans retinal
+ mini-Go 
+ arrestin
+ Gt peptide
(-)
(-)
2A
5G53 + agonist NECA 
2YDV + agonist NECA
4UG2 + agonist Cgs 21680
5WF5 + agonist UK-432097
+ mini-Gs 
(-)
(-)
(+ T4L)
6B3J + agonist exendin-P5 
5NX2 + agonist truncated peptide
+ Gs 
(-)
TM6TM5
B
Gi/o protein
ActiveInactive
11-cis retinal
Rhodopsin
all-trans 
retinalLight
G protein subtype– 
Gs protein
Diffusible 
agonist
ActiveInactive
A2AR
Fig. 6. Conformational changes upon GPCR activation. (A) Comparison between active conformations of rhodopsin, A2AR, and GLP-1R, respectively. We chose 
these receptors because their structures have been solved in different active and intermediate-active states. The superimposed structures are shown from the 
cytoplasmic side. We highlight the location of TM5 and TM6 to assist in visualizing the opening of the effector-binding site. (B) The top panel depicts the struc-
tural intermediates during rhodopsin activation. Light-induced retinal isomerization results in the formation of a predefined binding pocket for a Gi/o protein or 
arrestin. On the other hand, the bottom panel depicts how binding of diffusible ligands results in the formation of transient active GPCR conformations with 
higher conformational heterogeneity than active rhodopsin. In this case, the G protein likely selects and stabilizes a suitable conformation of the binding pocket 
from this ensemble.
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F and Endo F1 were tested, and only Endo F1 rendered a homogeneous 
deglycosylated product, which was confirmed by SDS-PAGE (fig. S1C).
Crystallization and synchrotron data collection
Crystallization of the gel-filtrated rhodopsin/mini-Go complex was 
set up using the vapor diffusion method. Crystallization drops were 
dispensed using a mosquito crystallization robot by mixing 200 nl 
of protein and 200 nl of crystallization buffer containing 0.1 M MES 
(pH 5.5) and 10 to 20% polyethylene glycol 4000 (PEG 4000) in an 
MRC 2-well crystallization plate (Swissci) at 4°C. Sword- or rod-
shaped crystals appeared in 1 to 3 days, and crystals wider than 10 m 
mainly grew from drops using the crystallization buffer containing 
13 to 17% PEG 4000. Before crystals were harvested on crystal loops 
(MiTeGen), crystals were cryoprotected by adding 400 nl of mother 
liquor supplemented with 10% glycerol or 10% trehalose to the crys-
tallization drop 1 day before harvesting. Harvested crystals were flash- 
frozen in liquid nitrogen (fig. S1B). Frozen crystals were evaluated 
at the PXI beamline at the Swiss Light Source (SLS) using raster 
scanning to identify the best diffracting locations on a frozen crystal. 
Diffraction datasets were collected by exposing crystals to a 10- or 
20-m-sized beam with 0.05° oscillation angle per frame.
Refinement and model building
Individual diffraction datasets were analyzed using XDS (45) for in-
tegrating Bragg peaks. All datasets showed the same unit cell di-
mensions with negligible deviation (less than 0.5%) and space group 
p61. The best five datasets were chosen for merging together to im-
prove the signal-to-noise ratio. The datasets were combined using 
XSCALE without scaling and merging, and the pooled reflection list 
was further analyzed using the STARANISO server (Global Phasing 
Ltd.). The STARANISO server first analyzed the anisotropy for each 
dataset, giving a resolution of 3.69 Å in the hk plane and 3.11 Å in 
the l direction using the criterion of CC1/2 = 0.3. The scaling factor 
was determined and applied after applying the anisotropic mask. After 
scaling, the datasets were merged, and the final resolution was improved 
to 3.02 Å and anisotropically truncated to 3.12 Å in the best direction 
(table S1). Structures of rhodopsin (PDB ID: 4A4M) and mini-Gs 
(PDB ID: 5G53) were used as search models to perform molecular 
replacement with the program Phaser. The sequence of mini-Go was 
modeled using the Swiss-Prot server (46). Structure refinement was per-
formed using phenix.refine (47) and Rosetta refinement (48) from the 
Phenix suite. Manual model-building and adjustment of the co-
ordinates were performed using the visualization program Coot. 
Polder maps (49) to verify the presence of retinal were calculated with 
Phenix using a low-resolution cutoff of 20 Å. For the retinal-only 
polder omit map, three cross-correlations were calculated between 
the following maps: (i) calculated Fobs with and without ligand (0.70), 
(ii) calculated and real Fobs with ligand (0.85), and (iii) calculated and 
real Fobs without ligand (0.77). These results verified the presence of 
retinal (fig. S3). In the Fobs-Fcalc (observed and calculated structure 
factors) map, there is a strong peak density above the 5 cutoff, 
and a water molecule was accordingly modeled into this position. The 
outlier in the Ramachandran plot (R206 in the 3-2 loop of mini-
Go) was likely caused by a crystal contact with ICL3 of rhodopsin in 
a symmetry- related complex molecule.
Comparison and analysis of structures
Structural models were downloaded from the Protein Data Bank. 
RMSDs (table S2) were obtained by superimposing the 3D struc-
tures with the super command in PyMOL (Schrödinger). The contacts 
between receptors and G proteins (Figs. 2 and 4A) were identified 
by selecting atoms within <4 Å cutoff. Figures were prepared using 
PyMOL.
SUPPLEMENTARY MATERIALS
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content/full/4/9/eaat7052/DC1
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Fig. S5. Sequence alignment of Gi/o proteins, mini-Go, and Gt peptide.
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